Dapagliflozin cost-saving alternative to DPP-4 inhibitors in T2DM

  • PDF / 169,730 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 74 Downloads / 224 Views

DOWNLOAD

REPORT

73-5503/20/0860-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 22 Aug 2020 No. 860

1

Data Loading...

Recommend Documents
Dapagliflozin as add-on to metformin may reduce T2DM burden in China

150 58 163KB

Dapagliflozin

137 57 167KB

Atorvastatin cost effective in T2DM

163 57 182KB

Dapagliflozin/empagliflozin

145 83 167KB

Canagliflozin/dapagliflozin

168 110 165KB

Vascular complications predict resource use in T2DM

156 32 121KB

Dapagliflozin/lidocaine/metformin

156 44 168KB

Resistance to Aromatase Inhibitors in Breast Cancer

115 56 6MB

Resistance to Tyrosine Kinase Inhibitors

167 28 3MB

Canagliflozin in T2DM-related nephropathy improves QALYs, reduces cost

181 44 164KB

Introduction to Alternative Investment Operations

167 67 2MB

DiRECT weight management programme cost effective in T2DM

144 97 167KB